28P - Pre-existing antitumor CD4 Th1 immunity in blood and PD-1/TIM-3+ CD4 T cells predict distinct outcome in lung cancer (28P)

Date 08 December 2017
Event ESMO Immuno-Oncology Congress 2017
Session Lunch & Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Bioethics, Legal, and Economic Issues
Presenter Magalie Dosset
Citation Annals of Oncology (2017) 28 (suppl_11): xi6-xi29. 10.1093/annonc/mdx711
Authors M. Dosset1, C. Laheurte1, D. Vernerey2, E. Lauret Marie Joseph1, L. Rangan1, E. Fabre3, F. Le Pimpec-Barthes3, E. Tartour3, G. Eberst2, V. Kaulek2, M. Jacquin2, V. Westeel2, C. Borg2, Y. Godet1, O. Adotevi2
  • 1Interactions Hôte-greffon-tumeur, Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, 25000 - Besançon/FR
  • 2Department Of Medical Oncology, University Hospital of Besançon, 25000 - Besançon/FR
  • 3Department Of Medical Oncology, European George Pompidou Hospital, 25000 - Besançon/FR



The IFN-ɣ+CD4 Th1 response plays a critical role in anticancer immunity and has been extensively studied from tumor microenvironment in many cancers. Evidence support that blood represents a crossroads site in which the cancer immunity also takes place. Here we aimed to characterize the natural history of a tumor-specific Th1 immunity in blood that can provide relevant information about cancer evolution.


Peripheral blood mononuclear cells were collected from 170 patients with non-small cell lung cancer (NSCLC) before any treatment. The presence of IFN-ɣ+ CD4 T cell response against telomerase (TERT) was used as surrogate marker of the antitumor Th1. The anti-TERT Th1 response was measured by ELISpot after stimulation of PBMC with promiscuous epitopes from TERT. Flow cytometry and multiplex beads assay were used to measure multiple immune cells and soluble factors in blood.


59 pts (35%) exhibited a pre-existing anti-TERT Th1 immunity. The frequency of anti-TERT Th1 responders decreased from localized to metastatic NSCLC (44.8% vs 24%, p 


Our data demonstrate a striking link between the systemic anti-TERT Th1 response with tumor burden and clinical outcome. It also provides evidence that the association of exhausted T cells and anti-TERT Th1 immunity monitoring could be used as a relevant blood-based dynamic immune biomarker.

Clinical trial identification

Legal entity responsible for the study

Olivier Adotévi


Assistance Publique des Hopitaux de Paris (AP-HP), FEDER-FUI, Ligue Nationale contre le Cancer


All authors have declared no conflicts of interest.